NIH expands clinical trials to test convalescent plasma against COVID-19

(NIH/National Center for Advancing Translational Sciences (NCATS)) Two randomized, placebo-controlled clinical trials funded by the NIH are expanding enrollment to further evaluate convalescent plasma as a treatment for patients hospitalized with COVID-19. Such trials may help determine whether convalescent plasma -- antibody-containing blood plasma from people who recovered from COVID-19 -- is an effective and safe treatment. The National Center for Advancing Translational Sciences will oversee...